Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
13F HOLDINGS REPORT

Atlas Venture Life Science Advisors, LLC

Quarter ended Q1 2025 · Filed May 14, 2025 · Accession 0001104659-25-048527

Total Value
$521.8M
Positions
13
Other Managers
0
Confidential Omitted
No
View on SEC.gov

Holdings (13)

#IssuerTicker / CUSIPSharesValue% of Filing
1Kymera Therapeutics, Inc.KYMR4,896,462$134.0M25.69%
2Disc Medicine, Inc.IRON2,384,456$118.4M22.69%
3Dyne Therapeutics, Inc.DYN9,130,465$95.5M18.30%
4Day One Biopharmaceuticals, Inc.DAWN6,430,257$51.0M9.77%
5Sionna Therapeutics, Inc.SION3,694,020$38.6M7.41%
6Third Harmonic Bio, Inc.88427A10710,402,286$36.1M6.92%
7Korro Bio, Inc.KRRO1,137,149$19.8M3.79%
8Vigil Neuroscience, Inc.92673K1085,836,874$10.4M1.99%
9Ikena Oncology, Inc.45175G1085,018,178$6.4M1.23%
10Aerovate Therapeutics, Inc.0080641071,799,232$4.5M0.87%
11Q32 Bio, Inc.QTTB2,092,106$3.5M0.66%
12Generation Bio, Co.37148K1008,279,484$3.4M0.64%
13Spero Therapeutics, Inc.SPRO305,255$219,7840.04%